This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look at the efficacy of Mavacamten as a treatment of hypertrophic cardiomyopathy
Ticker(s): BMYWho's the expert?
Institution: Harbor-UCLA Medical Center
- Associate Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA and a practicing interventional cardiologist at Harbor-UCLA Medical Center where he serves as the Medical Director of the Structural Heart Disease Program.
- Areas of expertise include coronary artery disease and structural and valvular heart disease while specializing in complex percutaneous coronary interventions including the use of rotational atherectomy.
- He has a research interest in therapies that improve cardiovascular disease outcomes.
Interview GoalDiscussing the potential of Mavacamten, the treatment of symptomatic obstructive hypertrophic cardiomyopathy and landscape of other cardiovascular drugs
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
